Thursday, 15 November 2018

Lupin brings generic antibiotic inhalation solution in US market

14 June 2018 | News

The company's Tobramycin Inhalation Solution USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml

Drug firm Lupin today said it has launched its antibiotic Tobramycin inhalation solution in the US market.

 

The company has launched the product as it has received an approval from the US Food and Drug Administration (USFDA) earlier, Lupin said.

 

The company's Tobramycin Inhalation Solution USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml, it added.

 

The product is indicated for the management of cystic fibrosis patients with P aeruginosa, Lupin said.

 

As per IQVIA MAT April 2018 data, Tobramycin inhalation solution USP, 300 mg/5 ml, had annual sales of nearly USD 99 million in the American market, it added.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Click Here!




Survey Box

Will the health insurance sector receive benefits from Ayushman Bharat?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls